Darzalex (daratumumab)

drip
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Darzalex (daratumumab)

How to buy Darzalex: You can order Darzalex (daratumumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Janssen Biotech
Disease Blood Cancer
Indication Multiple Myeloma
Mode of Action Monoclonal antibody (immunotherapy)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
CAS Number 945721-28-8
HS Code 30021091
Strength 20 mg/mL

Who is daratumumab for?

Daratumumab is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent [1][2][8]; or as second line treatment of multiple myeloma in combination with other medicines, namely lenalidomide and dexamethasone, or bortezomib and dexamethasone [1][3][8].

Recommended dose

Complete information about daratumumab dosage and administration can be found here [1][3].
The recommended dose is 16 mg/kg body weight according to the following schedule.
As monotherapy and in combination with lenalidomide and low-dose dexamethasone:
  • weekly infusions for week 1–8 (total of 8 infusions)
  • from week 9–24 every 2 weeks (total of 8 infusions)
  • from week 25 onwards until disease progression every four weeks [1][3].
In combination with bortezomib and dexamethasone:
  • weekly infusions for week 1–9 (total of 9 infusions)
  • from week 10–24 every 3 weeks (total of 5 infusions)
  • from week 25 onwards until disease progression every four weeks [1].
Consult your treating doctor for personalised dosing.

What is daratumumab and how does it work?

Daratumumab is a human CD38-directed monoclonal antibody indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent [1].
Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white blood cell) found in the bone marrow. These cancerous cells multiply, producing an abnormal protein and pushing out other healthy blood cells from the bone marrow [4]. Daratumumab is a monoclonal antibody that works by helping certain cells in the immune system attack these cancer cells [4]. One of the antigens expressed on the surface of multiple myeloma cells is called CD38. Anti-CD38 antibodies, like daratumumab, target multiple myeloma cells by binding to the CD38 antigen and then signaling the patient’s immune system to attack the tumour [5].

What is daratumumab approval status?

Darzalex (daratumumab) was approved by:
  • FDA (USA) on November 16, 2015 [4]
  • EMA (EU) on May 20, 2016 [2]
  • TGA (AUS) on July 17, 2017 [8]
for multiple myeloma as monotherapy, for the treatment of patients who have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent [3][4][8]. Daratumumab is also indicated as second-line treatment in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone [1][3][7][8].
The approvals of daratumumab as monotherapy were partly based on two studies that returned positive results. In study MMY2002 31 of the 106 patients treated with daratumumab experienced a complete or partial reduction in their tumour burden (overall response rate (ORR) = 29.2 %; 95 % confidence interval (CI) 20.8, 38.9), which lasted for an average of 7.4 months [6][1][3]. The median overall survival (OS) was 17.5 months [3]. The second study (GEN501), involving 42 participants, resulted in a complete or partial reduction of the tumour for 36 % of the patients. The median duration of response was not reached and after 15.2 months 74 % of the patients were still alive [3].
The approval of daratumumab in combination with lenalidomide and dexamethasone was based on a study which compared treatment with daratumumab in combination with lenalidomide and dexamethasone (DLD) (N = 286) to lenalidomide and dexamethasone (LD) alone (N = 283) in 569 patients with multiple myeloma who had received at least one prior treatment. The OS in the DLD was 91.3 % vs 74.6 %. The median progression free survival (mPFS) was 18.4 months in the LD group while it was not reached in the DLD arm. The risk of disease progression or death in the DLD group was reduced by 63 % in the DLD arm compared to the LD arm [1].
The approval of daratumumab in combination with bortezomib and dexamethasone was based on a study which compared treatment with daratumumab in combination with bortezomib and dexamethasone (DBD) (N = 251) to bortezomib and dexamethasone (BD) alone (N = 247) in 498 patients with multiple myeloma who had received a median of 2 prior treatments. The mPFS was 7.2 months in the BD group while it was not reached in the DBD arm. The risk of disease progression or death in the BD group was reduced by 61 % in the DBD arm compared to the BD arm [1].
References
[1] Summary of Product Characteristics: Darzalex (daratumumab), Janssen Biotech Inc, FDA, Nov. 2016.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl.pdf
[2] EMA. Human Medicines: Darzalex (daratumumab), 27/05/2016 (last update: 02/06/2017), cited on 18/01/2016.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004077/human_med_001979.jsp&mid=WC0b01ac058001d124
[3] Summary of Product Characteristics: Darzalex (daratumumab), Janssen-Cilag International, EMA, July 2017.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004077/WC500207296.pdf
[4] FDA News Release: FDA approves Darzalex for patients with previously treated multiple myeloma, 16/11/2015.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472875.htm
[5] Helwick C., Strong Showing for Anti-CD38 Antibodies in Multiple Myeloma. The ASCO Post. 10/02/2015.
http://www.ascopost.com/issues/february-10,-2015/strong-showing-for-anti-cd38-antibodies-in-multiple-myeloma.aspx
[6] Lional S., et al. Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). J Clin Oncol. 2015 Jun. 2; 33
http://meetinglibrary.asco.org/content/150339-156
[7] European Commission grants expanded label for Darzalex. The pharma letter. 29/04/2017.
https://www.thepharmaletter.com/article/european-commission-grants-expanded-label-for-darzalex
[8] TGA. Public Summary: Darzalex (daratumumab).
https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=9791BBA782AF92C3CA258160004211C7&agid=(PrintDetailsPublic)&actionid=1

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.